METHODS	Patients with Stage III and IV ( UICC ) unresectable oro - and hypopharyngeal carcinomas were randomized for HF-ACC-RCT with 2 cycles of 5-FU ( 600 mg/m ( 2 ) / day ) / carboplatinum ( 70 mg/m ( 2 ) ) on days 1 -- 5 and 29 -- 33 ( arm A ) or HF-ACC-RT alone ( arm B ) .\